Integrated Digital Batch Release: A Conceptual Framework for Compressing Administrative Latency Without Compromising Decision Integrity
Keywords
Drug Industry Quality Control Digital Technology Data Accuracy Batch ReleaseAbstract
Background: Digital transformation is often proposed to accelerate the batch release process in the pharmaceutical industry; however, this release process encompasses both administrative aspects and professional decision-making with attendant responsibilities. This conceptual paper develops an Integrated Digital Batch Release (IDBR) framework to identify activities that can be streamlined through the integration of digital evidence, while maintaining the quality of decision-making. Methodology: A conceptual framework analysis and purposive narrative mapping review the literature on digital transformation, batch records, data integrity, quality systems, human-automation interactions, and their implementation. A case study in the Indonesian pharmaceutical industry served as the basis for defining the problem scope; however, the baseline data from the case has not been verified. Results: IDBR distinguishes administrative latency from the evaluative core and defines release proof readiness. Five mechanisms address administrative latency: provenance-integrated access, ownership-based handover, readiness visibility, administrative checkpoints, and data integrity governance. Decision quality invariance is proposed as a safeguard. The framework establishes boundary conditions, design tensions, eight propositions, and a measurement architecture. Conclusions: IDBR conceptualized digital batch release as an effort to reduce administrative delays while maintaining professional evaluation. This concept has not been empirically validated. Implications: Quality and digital transformation managers can use this framework to guide baseline time studies, phased trials, and evaluations that combine administrative efficiencies with security measures to ensure quality decision-making
References
1. European Commission. EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. Annex 16: Certification by a Qualified Person and Batch Release. Revision 1. Brussels: European Commission; 2016.
2. Badan Pengawas Obat dan Makanan Republik Indonesia. Peraturan Badan Pengawas Obat dan Makanan Nomor 7 Tahun 2024 tentang Standar Cara Pembuatan Obat yang Baik. Berita Negara Republik Indonesia Tahun 2024 Nomor 271. Jakarta: BPOM; 2024. Sebagaimana diubah dengan Peraturan Badan Pengawas Obat dan Makanan Nomor 7 Tahun 2025 tentang Perubahan atas Peraturan Badan Pengawas Obat dan Makanan Nomor 7 Tahun 2024 tentang Standar Cara Pembuatan Obat yang Baik. Berita Negara Republik Indonesia Tahun 2025 Nomor 208. Jakarta: BPOM; 2025.
3. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: preparing for the smart factories of the future. Int J Pharm. 2021;602:120554. doi:10.1016/j.ijpharm.2021.120554.
4. International Society for Pharmaceutical Engineering. ISPE Baseline® Guide: Pharma 4.0™. 1st ed. North Bethesda: ISPE; 2023.
5. Fitzgerald L, Niarchou E, Jones I, Naughton B. Emerging digital innovations in pharmaceutical manufacturing quality: a systematised review. J Pharm Innov. 2026;21:46. doi:10.1007/s12247-025-10272-5.
6. Marsh J, Eyers D. Increasing production efficiency through electronic batch record systems: a case study. In: Setchi R, Howlett RJ, Liu Y, Theobald P, editors. Sustainable Design and Manufacturing 2016. Smart Innovation, Systems and Technologies. Vol 52. Cham: Springer; 2016. p. 261-269. doi:10.1007/978-3-319-32098-4_23.
7. Vial G. Understanding digital transformation: a review and a research agenda. J Strateg Inf Syst. 2019;28(2):118-144. doi:10.1016/j.jsis.2019.01.003.
8. US Food and Drug Administration. Computerized systems in drug establishments (2/83) [Internet]. Silver Spring (MD): FDA; 1983 [cited 2026 Nov 8]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/computerized-systems-drug-establishments-28.
9. Wulansari D, Nurlativah E, Marpaung SUA, Baiti ZH. Integrated digital batch release: transformasi pelulusan produk berbasis integrasi sistem mutu [innovation challenge proposal]. Master of Pharmacy Program, Universitas Pancasila; 2026. Unpublished Report.
10. Lyell D, Coiera E. Automation bias and verification complexity: a systematic review. J Am Med Inform Assoc. 2017;24(2):423-431. doi:10.1093/jamia/ocw105.
11. Lyell D, Magrabi F, Raban MZ, Pont LG, Baysari MT, Day RO, et al. Automation bias in electronic prescribing. BMC Med Inform Decis Mak. 2017;17:28. doi:10.1186/s12911-017-0425-5.
12. World Health Organization. Guideline on data integrity. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report. WHO Technical Report Series No. 1033, Annex 4. Geneva: World Health Organization; 2021.
13. Medicines and Healthcare products Regulatory Agency. GxP data integrity guidance and definitions [Internet]. London: MHRA; 2018 [updated 2021 Sep 27]. Available from: https://www.gov.uk/government/publications/guidance-on-gxp-data-integrity
14. Pharmaceutical Inspection Co-operation Scheme. Good practices for data management and integrity in regulated GMP/GDP environments. PI 041-1. Geneva: PIC/S; 2021 Jul 1. Available from: https://picscheme.org/layout/document.php?id=714
15. Abdulhussain R, Muhamad H, Fiza T, Dereiah S, Mawla N, Patel K, et al. The integration of artificial intelligence through quality by digital design for sustainable pharmaceutical manufacturing. Int J Pharm. 2026;693:126682.
16. Charoo NA, Khan MA, Rahman Z. Data integrity issues in pharmaceutical industry: common observations, challenges and mitigations strategies. Int J Pharm. 2023;631:122503. doi:10.1016/j.ijpharm.2022.122503
17. Hock SC, Tay V, Sachdeva V, Wah CL. Pharmaceutical data integrity: issues, challenges and proposed solutions for manufacturers and inspectors. GaBI J. 2020;9(4):171–82. doi:10.5639/gabij.2020.0904.028
18. Rattan AK. Data integrity: history, issues, and remediation of issues. PDA J Pharm Sci Technol. 2018;72(2):105–16. doi:10.5731/pdajpst.2017.007765
19. Pedro F, Veiga F, Mascarenhas-Melo F. Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: how obvious is it? Drug Discov Today. 2023;28(11):103759.
20. Gokulakrishnan D, Venkataraman S. Ensuring data integrity: best practices and strategies in pharmaceutical industry. Intell Pharm. 2025;3(4):296–303. doi:10.1016/j.ipha.2024.09.010
21. Vignesh M, Ganesh GNK. Current status, challenges and preventive strategies to overcome data integrity issues in the pharmaceutical industry. Int J Appl Pharm. 2020;12(6):19–23. doi:10.22159/ijap.2020v12i6.38987
22. US Food and Drug Administration. Data integrity and compliance with drug CGMP: questions and answers. Guidance for industry. Silver Spring: FDA; 2018.
23. International Society for Pharmaceutical Engineering. ISPE GAMP 5 guide: a risk-based approach to compliant GxP computerized systems. 2nd ed. North Bethesda: ISPE; 2022.
24. European Commission. EudraLex Volume 4: EU guidelines for good manufacturing practice. Annex 11: computerised systems. Brussels: European Commission; 2011.
25. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q9(R1): quality risk management. Geneva: ICH; 2023.
26. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q10: pharmaceutical quality system. Geneva: ICH; 2008.
27. Rogers EM. Diffusion of innovations. 5th ed. New York: Free Press; 2003.
28. Greenhalgh T, Wherton J, Papoutsi C, Lynch J, Hughes G, A'Court C, et al. Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. J Med Internet Res. 2017;19(11):e367.
29. Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022;17:75.
30. Jabareen Y. Building a conceptual framework: philosophy, definitions, and procedure. Int J Qual Methods. 2009;8(4):49–62.
31. Whetten DA. What constitutes a theoretical contribution? Acad Manage Rev. 1989;14(4):490–5.
32. Jaakkola E. Designing conceptual articles: four approaches. AMS Rev. 2020;10:18–26.
33. Walker LO, Avant KC. Strategies for theory construction in nursing. 6th ed. New York: Pearson; 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Public Health Industry

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




